- $119.46m
- $46.25m
- $130.38m
- 38
- 52
- 27
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.97 | ||
| Price to Tang. Book | 0.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -65.68% | ||
| Return on Equity | -93.69% | ||
| Operating Margin | -130.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.08 | 49.94 | 102.6 | 115.38 | 130.38 | 148.17 | 174.16 | 130.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Outset Medical, Inc. is a medical technology company. The Company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The Company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
Directors
- D. Keith Grossman NEC (61)
- Leslie Trigg PRE (50)
- Nabeel Ahmed CFO (45)
- Martin Vazquez COO (51)
- John Brottem GCN (47)
- Steven Williamson OTH (48)
- Catherine Szyman DRC (54)
- Karen Drexler IND (61)
- Patrick Hackett IND (59)
- James Hinrichs IND (53)
- Andrea Saia IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 5th, 2003
- Public Since
- September 15th, 2020
- No. of Shareholders
- 102
- No. of Employees
- 480
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 51,492,317
- Address
- 3052 Orchard Drive, SAN JOSE, 95134
- Web
- https://outsetmedical.com/
- Phone
- +1 9715633083
- Auditors
- KPMG LLP
Upcoming Events for OM
Q1 2024 Outset Medical Inc Earnings Call
Outset Medical Inc Annual Shareholders Meeting
Outset Medical Inc Annual Shareholders Meeting
Q2 2024 Outset Medical Inc Earnings Release
Q3 2024 Outset Medical Inc Earnings Release
Similar to OM
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Outset Medical share price?
As of Today at 19:16 UTC, shares in Outset Medical are trading at $2.32. This share price information is delayed by 15 minutes.
How has the Outset Medical share price performed this year?
Shares in Outset Medical last closed at $2.32 and the price had moved by -87% over the past 365 days. In terms of relative price strength the Outset Medical share price has underperformed the S&P500 Index by -89.18% over the past year.
What are the analyst and broker recommendations for Outset Medical?
The overall consensus recommendation for Outset Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Outset Medical dividend yield?
Outset Medical does not currently pay a dividend.
Does Outset Medical pay a dividend?
Outset Medical does not currently pay a dividend.
When does Outset Medical next pay dividends?
Outset Medical does not currently pay a dividend.
How do I buy Outset Medical shares?
To buy shares in Outset Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Outset Medical?
As of the previous close price of $2.32, shares in Outset Medical had a market capitalisation of $119.46m.
Where are Outset Medical shares listed?
Here are the trading details for Outset Medical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OM
What kind of share is Outset Medical?
Based on an overall assessment of its quality, value and momentum Outset Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Outset Medical share price forecast for 2024?
The analyst consensus target price for shares in Outset Medical is $5.79. That is 149.57% above the last closing price of $2.32.
Analysts covering Outset Medical currently have a consensus Earnings Per Share (EPS) forecast of -$2.07 for the next financial year.
What is the trend in the Outset Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Outset Medical. Over the past six months, its share price has underperformed the S&P500 Index by -46.33%.
As of the last closing price of $2.32, shares in Outset Medical were trading -69.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Outset Medical PE Ratio?
The Outset Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Outset Medical?
Outset Medical's management team is headed by:
- D. Keith Grossman - NEC
- Leslie Trigg - PRE
- Nabeel Ahmed - CFO
- Martin Vazquez - COO
- John Brottem - GCN
- Steven Williamson - OTH
- Catherine Szyman - DRC
- Karen Drexler - IND
- Patrick Hackett - IND
- James Hinrichs - IND
- Andrea Saia - IND